|
|
|
 |
|
Validation of Biomarkers in Amyotrophic Lateral Sclerosis (ALS) (BIO_ALS-01) |
|
|
| |
 |
 |
 |
 |
Study Focus: The purpose of this study is to collect biofluid samples for the banking and usage in ALS research. |
 |
Disease: Amyotrophic Lateral Sclerosis (ALS), Sporadic ALS, Familial ALS, Primary Lateral Sclerosis (PLS), Hereditary Spastic Paraplegia (HSP), Healthy Volunteer, Other: Disease Mimics of ALS |
 |
Study Category: Biomarkers/imaging |
 |
Study Status: Active, no longer recruiting |
 |
Phase: Not Applicable |
 |
Type: Observational Study |
 |
|
 |
Funding Source: ALSA, ATA, NIH |
 |
Study Chair(s)/Principal Investigator(s): Merit Cudkowicz, MD, MSc (Massachusetts General Hospital)
James D. Berry, MD, PhD (Massachusetts General Hospital)
Robert Bowser, PhD (Barrow Neurological Institute) |
 |
Clinicaltrials.gov ID: NCT00677768 |
 |
Study ID: BIO_ALS-01 |
 |
NEALS Affiliated? Yes
 |
|
|
 |
 |
|
 |
 |
Study Summary: The purpose of this study is to collect 650 blood and 300 cerebrospinal fluid (CSF) samples from people with amyotrophic lateral sclerosis (ALS), pure lower or upper motor neuron diseases, as well as other neurodegenerative diseases and from people with no neurological disorder. Through comparison of these samples, the researchers hope to learn more about the underlying cause of ALS, as well as find unique biological markers, which could be used to diagnose ALS and monitor disease progression.
Additionally, up to 600 blood samples will be collected for a sub-study for DNA analysis. Studying components of the blood, such as DNA, may help us understand what happens when genes function abnormally and how it might be related to disease.
|
 |
Participant Duration: Up to 36 months |
 |
# of Subjects: 650 |
 |
Enrollment Start Date: 05/01/2008 |
 |
Enrollment End Date: 12/01/-0001 |
 |
Posting Last Modified Date: 12/01/2011 |
 |
Date Study Added to alscortium.org: 11/01/2011 |
 |
More information: Researchers tested what changes happen in volunteers with ALS that can be seen in the blood and what changes are unique to ALS and are different from those found in healthy volunteers and volunteers with neurological diseases other than ALS. These changes are called biomarkers. Biomarkers for ALS have been found in blood collected in earlier phases of this study. Biomarkers are non-genetic elements in your blood that may help to make diagnosing ALS easier. In the next phase, comparison of these changes in the blood of volunteers with ALS and without ALS will be used to confirm these biomarkers and to develop a tool to diagnose and monitor progression of ALS. |
 |
| Eligibility Criteria |
 |
Gender: Male & Female |
 |
Minimum Age: 30 |
 |
Maximum Age: 80 |
 |
Min Vital Capacity (% predicted normal): N/A |
 |
Time since Symptom Onset: Less than 36 months |
 |
Can participants use Riluzole? Yes |
|
 |
Coordinating Center Contact Information |
 |
| Daniela Grasso |
 |
| dgrasso@partners.org |
 |
| 617-726-0842 |
 |
| NCRI at the Massachusetts General Hospital |
 |
149 13th Street, BLDG 149, MGH East Boston, Massachusetts 02129 UNITED STATES |
 |
|
 |
Other Eligibility Criteria: Medically safe to have lumbar puncture |
 |
|
 |
 |
|
 |
Site Contact Information (Please click to show/hide) |
|
|
 |
|
 |
 |
| Arizona |
 |
Phoenix Neurological Associates, Ltd
Todd Levine, MD / Nicole Hank, MHMS
levine865@aol.com / nhank@pnal.net
602-258-2432 / 602-258-2432
5090 N. 40th Street Suite 250 Phoenix, Arizona 85018 UNITED STATES |
 |  |
| California |
 |
UC Irvine MDA ALS and Neuromuscular Center
Tahseen Mozaffar, MD / Veronica Martin
mozaffar@uci.edu / vero@uci.edu
714-456-5214 / 714-456-7760
200 S Manchester Avenue Suite 110 Orange, California 92868 UNITED STATES |
 |  |
| Florida |
 |
Mayo Clinic Neurology
Kevin Boylan, MD / Thomas Kryston
boylan.kevin@mayo.edu / kryston.thomas@mayo.edu
904-953-6915 / 904-953-8344
Cannaday 2E 4500 San Pablo Road Jacksonville, Florida 32224 UNITED STATES |
 |
University of Miami Miller School of Medicine
Khema Sharma, MD / Donald Koggan, MD
ksharma@med.miami.edu / dkoggan@med.miami.edu
305-243-5586 / 305-243-7424
Clinical Research Building, 1375-1 1120 NW 14 Street Miami, Florida 33136 UNITED STATES |  |
| Georgia |
 |
Emory University
Jonathan Glass, MD / Latoya Shaw / Crystal Richards
jglas03@emory.edu / lqshaw@emory.edu / cricha6@emory.edu
404-727-3507 / 404.727.1673 / 404-727-3813
The ALS Center at Emory University 101 Woodruff Circle, Suite 6000 Atlanta, Georgia 30322 UNITED STATES |
 |  |
| Illinois |
 |
University of Chicago Medical Center
Raymond Roos, MD / Koroush Rezania, MD / Ismael Gutierrez
rroos@neurology.bsd.uchicago.edu / krezania@neurology.bsd.uchicago.edu / igutierr@neurology.bsd.uchicago.edu
773-702-5659 / 773-702-9200 / 773-834-4654
Department of Neurology 5841 South Maryland Avenue, MC 2030 Chicago, Illinois 60637 UNITED STATES |
 |  |
| Maryland |
 |
Johns Hopkins University - ALS Clinic
Nicholas Maragakis, MD / Elizabeth (Betsy) Mosmiller
nmaragak@jhmi.edu / emosmil1@jhmi.edu
410-614-9874 / 410-502-0495
601 N. Caroline Street Neurology, 5th Floor, Suite 5070 Baltimore, Maryland 21205 UNITED STATES |
 |  |
| Massachusetts |
 |
Lahey Clinic
James Russell, DO / Stephanie Scala
james.a.russell@lahey.org / stephanie.a.scala@lahey.org
781-744-8632 / 781-744-2950
31 Mall Road Burlington, Massachusetts 01805 UNITED STATES |
 |
Massachusetts General Hospital
Merit Cudkowicz, MD, MSc / James Berry, MD, PhD / Robert Lawson
mcudkowicz@partners.org / jdberry@partners.org / rjlawson@partners.org
617-724-1873 / 617-726-5097 / 617-726-0563
149 13th Street CNY, Room 2274 Charlestown, Massachusetts 02129 UNITED STATES |  |
| Michigan |
 |
Saint Mary's Healthcare
Deborah Gelinas, MD / Brian Berryhill, PharmD.
gelinasd@trinity-health.org / berryhib@trinity-health.org
616-685-5314 / 616-685-5435
Neuroscience Program 220 Cherry Street, SE Grand Rapids, Michigan 220 Cherry Street, SE UNITED STATES |
 |  |
| Minnesota |
 |
Hennepin County Medical Center / Berman Center
Ezgi Tiryaki, MD / Cindy Rohde
etiryaki@gmail.com / crohde@bermancenter.org
612-873-2595 #4 / 612-341-7923
825 South 8th Street, Suite 440 Minneapolis, Minnesota 55404 UNITED STATES |
 |  |
| Missouri |
 |
St Louis University
Ghazala Hayat, MD / Susan Eller, MA, RN
hayatm2@slu.com / ellersc@slu.edu
314-977-4860 / 314-977-4867
1438 South Grand CRU 3rd Floor St Louis, Missouri 63104 UNITED STATES |
 |
Washington University Medical School
Alan Pestronk, MD / Julaine Florence, DPT, PT / Charlie Wulf / Pamela Townsend
pestronka@neuro.wustl.edu / florencej@neuro.wustl.edu / wulfc@neuro.wustl.edu / townsendp@neuro.wustl.edu
314-362-6981 / 314-362-6983 / 314-362-6980
660 S. Euclid Avenue Box 8111 St Louis, Missouri 63110 UNITED STATES |  |
| New Hampshire |
 |
Dartmouth Hitchcock Medical Center
Brent Harris, MD
bharris@dartmouth.edu
603-650-0889
Dartmouth Medical School One Medical Center Drive, DHMC Lebanon, New Hampshire 03756 UNITED STATES |
 |  |
| New Jersey |
 |
UMDNJ Robert Wood Johnson Medical School
Jerry Belsh, MD / Barbara Belsh
belsh@umdnj.edu / belshba@umdnj.edu
732-235-7340 / 732-235-7234
Department of Neurology 97 Patterson Street New Brunswick, New Jersey 08901 UNITED STATES |
 |  |
| New York |
 |
Upstate Clinical Research, LLC
James Wymer, MD / Suzanne Alterman, RN, BSN
jwymer@upstateneurology.com / salterman@upstateneurology.com
518-438-0922 / 518-533-1546
3 Atrium Drive Suite 205 Albany, New York 12205 UNITED STATES |
 |
Beth Israel Medical Center, PACC
Stephen Scelsa, MD / Theresa Imperato
sscelsa@chpnet.org / imperato@als-ny.org
212-844-8490 / 516-946-5467
10 Union Square East Suite 5D New York, New York 10003 UNITED STATES |  |
SUNY Upstate Medical University
Jeremy Shefner, MD / Katie Markis / Mary Lou Watson, RRT
shefnerj@upstate.edu / markisk@upstate.edu / watsonm@upstate.edu
315-464-5302 / 315-464-4998 / 315-464-5004
Institute for Human Performance Clinical Research Unit 505 Irving Avenue Syracuse, New York 13210 UNITED STATES |
 |  |
| North Carolina |
 |
Carolinas Health Care
Benjamin Brooks / Jaime Shue, RN, BSN / Brent Harris, MD
benjamin.brooks@carolinashealthcare.org / jaime.shue@carolinashealthcare.org / bharris@dartmouth.edu
704-446-1910 / 704-446-6253 / 603-650-0889
1010 N. Edgehill Road Charlotte, North Carolina 28207 UNITED STATES |
 |
Duke University Medical Center
Richard Bedlack, MD / Karen Grace, RN
bedla001@mc.duke.edu / karen.grace@duke.edu
919-668-2639 / 919-668-2844
Neuroscience Clinical Research Organization 932 Morreene Road, Room 213 Durham, North Carolina 27705 UNITED STATES |  |
Wake Forest University Baptist Medical Center
James Caress, MD / Mozhdeh Marandi, MD, CCRC / Theresa Johnston-Crews, RN, MSN
jcaress@wfubmc.edu / mmarandi@wfubmc.edu / tjcrews@wfubmc.edu
336-716-6704 / 336-713-8577 / 336-716-2323
Medical Center Boulevard Ground Floor - Sticht Center Winston-Salem, North Carolina 27157 UNITED STATES |
 |  |
| Ohio |
 |
OSU Medical Center / Dept of Neurology
Stephen Kolb, MD / Sharon Chelnick
stephen.kolb@osumc.edu / sharon.chelnick@osumc.edu
614-293-4969 / 614-293-4973
395 W 12th Avenue 7th Floor Columbus, Ohio 43210 UNITED STATES |
 |  |
| Oregon |
 |
Oregon Health & Science University
Jau-Shin Lou, MD, PhD / Diana Dimitrova
louja@ohsu.edu / dimitrov@ohsu.edu
503-494-1769 / 503-494-7269
Dept of Neurology CR-120 3181 Sam Jackson Park Road Portland, Oregon 97233 UNITED STATES |
 |
Providence ALS Center
Kimberly Goslin, MD / Britt Ash, RN, BSN
kgoslin@orclinic.com / britt.ash@providence.org
503-963-3100 / 503-963-3128
5050 NE Hoyt Suite 315 Portland, Oregon 97213 UNITED STATES |  |
| Pennsylvania |
 |
Pennsylvania State University
Zachary Simmons, MD / Kevin Scott, MD / Helen (Beth) Stephens, MA
zsimmons@psu.edu / kscott@psu.edu / hstephens1@psu.edu
717-531-1802 / / 717-531-0003 x283395
Penn State Hershey Neuroscience Clinics, EC120, Room 1304 30 Hope Drive, PO Box 859 Hershey, Pennsylvania 17033 UNITED STATES |
 |
Drexel University College of Medicine
Terry Heiman-Patterson, MD / Christine Barr, RN
terry.heiman-patterson@drexelmed.edu / christine.barr@drexelmed.edu
215-762-7692 / 215-762-5186
219 North Broad Street 7th Floor, Department of Neurology Philadelphia, Pennsylvania 19107 UNITED STATES |  |
University of Pittsburgh
David Lacomis, MD / Danielle Rowlands, RN, BSN
lacomisd@upmc.edu / doerflerd@upmc.edu
412-647-1706 / 412-648-9053
BST S-514 200 Lothrop Street Pittsburgh, Pennsylvania 15213 UNITED STATES |
 |  |
| Quebec |
 |
Montreal Neurological Institute
Angela Genge, MD / Jo-Wen Wang
angela.genge@mcgill.ca / jo-wen.wang@mcgill.ca
514-398-3868 / 514-398-1779
380 University Street Suite 207 Montreal, Quebec H3A 2B4 CANADA |
 |  |
| Texas |
 |
Methodist Neurological Institute
Milvia Pleitez, MD / Luis Lay, Jr / Sharon Halton
MPleitez@tmhs.org / lflayjr@tmhs.org / slhalton@tmhs.org
713-441-3335 / 713-441-3057 / 713-441-3420
6560 Fannin, Suite 802 Houston, Texas 77030 UNITED STATES |
 |  |
| Utah |
 |
University of Utah
Mark Bromberg, MD / Narneice Craven
mbromberg@hsc.utah.edu / narneice.craven@hsc.utah.edu
801-585-5885 / 801-585-7876
30 North 1900 East Department of Neurology SOM3R210 Salt Lake City, Utah 84132 UNITED STATES |
 |
 |
|
 |
Familial ALS- ALS cases are inherited from 2 or more family members, affects 5-10% of ALS cases. Sporadic ALS- disease occurs at random with no clearly associated risk factors; most common form of ALS, affects approximately 90-95% ALS cases. Interventional trial- study where exposure, for example a drug, is assigned; used to determine the effectiveness of a treatment or intervention. With drugs and a placebo- One group gets the active treatment, the other gets the placebo. Everything else is held the same between the two groups, so that any difference in their outcome can be attributed to the active treatment. Observational study- study in which patients are observed and where no treatment is given; researcher has no control over the experiment because they are done in a more natural setting than an interventional trial. Trial Phase- objectives are different for each phase of a trial. - Phase I, drug is given to a small number of people to see if it is safe.
- Phase II begins to look at effectiveness of the drug.
- Phase III is considered the definitive test of whether a drug is effective, held at multiple research sites and much larger than the previous phases.
Vital Capacity- the maximum amount of air that can be expelled from the lungs after a maximum drawing of air into the lungs, measured by a spirometer and then scored as a percentage. |